Clinical Trial Update: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial updates on risk-based therapy for newly diagnosed hepatoblastoma in younger patients, with active status and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatoblastoma

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: PRETEXT I Hepatoblastoma, PRETEXT II Hepatoblastoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-12-28